FibroBiologics (Nasdaq: FBLG)

FibroBiologics (Nasdaq: FBLG) announces its participation at the 26th Annual H.C. Wainwright & Co., LLC Global Investment Conference. Conference attendees can access the presentation on-demand starting on September 9 at 7:00 AM ET. For more, please visit: https://bit.ly/3ZhcZ5R #InvestorRelations #InvestmentConference #Biopharma

FibroBiologics has filed a patent application for wound healing using an adhesive bandage that incorporates fibroblast cell-based technology that could lead to the development of a room-temperature, shelf-stable bandage. For more, please visit: https://bit.ly/4716vtG #WoundCare #PatentFiling

Dr. Hamid Khoja, Chief Scientific Officer of FibroBiologics (Nasdaq: FBLG) shares insights into our potentially groundbreaking work in wound healing by utilizing fibroblast-mediated therapies. By employing spheroids of specific fibroblast subtypes, Dr. Khoja and his team aim to accelerate the healing process and significantly reduce the recurrence rates of diabetic foot ulcers (DFU), which pose a significant challenge in patient care. For more about our science, please visit https://bit.ly/3xDByyw #WoundHealing #Innovation

Did you know? While stem cells often dominate discussions in regenerative medicine, fibroblasts could be equally vital. Serving as the primary cell type in connective tissue, fibroblasts produce and maintain the extracellular matrix crucial for tissue integrity, engage in immune modulation, and aid in the tissue remodeling phases of wound healing. Read more on what fibroblasts are: https://bit.ly/3xDByyw #RegenerativeMedicine #CellTherapy

FibroBiologics has filed its quarterly report for Q2 2024. This report includes updates on our ongoing efforts to develop fibroblast technology for treating chronic diseases. For more, please visit: https://bit.ly/3WW05bS #InvestorRelations #Biotech

Tune in to Pete O’Heeron, CEO of FibroBiologics (Nasdaq: FBLG), on the "Conversations Life Science Leaders Aren't Having" podcast hosted by Jeff Harmon. In this insightful episode, Pete discusses the potential of fibroblasts in tissue regeneration and chronic disease treatment, an area often overshadowed by stem cell research. Listen to how Pete’s leadership is paving the way for innovative approaches to healthcare. Apple Podcasts: https://apple.co/3Aez1vu Watch the interview here: https://bit.ly/4fwEnSZ #Biotech #HealthcareInnovation

Watch our leadership team discuss our mission to pioneer in #RegenerativeMedicine, underpinned by our commitment to innovation, urgency, teamwork, and inclusion. We extend our heartfelt thanks to our investors, whose support has been pivotal in reaching this stage. #Fibroblasts #HealthInnovation #CellTherapy

FibroBiologics’ CEO, Pete O’Heeron, will present today July 15, at 1:45 pm PT, at the JonesTrading Healthcare Summit 2024 in San Diego. Hear about our innovative approaches to using fibroblasts with an aim to treat chronic diseases. Register for the webcast: https://bit.ly/3W7thL4 #HealthcareInnovation #Biotech

Watch Dr. Neil Bhowmick, from Cedars-Sinai, and scientific advisor to FibroBiologics (Nasdaq: FBLG), share his insights on fibroblasts' pivotal role across various medical applications. Hear how Dr. Bhowmick highlights fibroblasts’ abundance and versatility—emphasizing their potential in #disease treatment, including #cancer and #lupus. For more about fibroblasts, please see: https://bit.ly/3xDByyw #Fibroblasts #HealthInnovation #CellTherapy

Join us on the HealthBiz podcast as Pete O'Heeron, CEO of FibroBiologics (Nasdaq: FBLG), shares his unique journey from his early influences in a medically oriented family to leading healthcare innovations. Discover how Pete’s experiences shaped his career path from pre-med to pioneering in fibroblasts, potentially revolutionizing tissue regeneration and chronic disease treatment. Apple Podcasts: https://apple.co/3LiQtBq YouTube: https://bit.ly/4cynlBQ #Innovation #HealthcareFuture Health Business Group